Detalhe da pesquisa
1.
PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma.
J Clin Invest
; 134(6)2024 Feb 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38319732
2.
Translational considerations for immunotherapy clinical trials in pediatric neuro-oncology.
Neoplasia
; 42: 100909, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37244226
3.
A review of the anti-tumor potential of current therapeutics targeting the mitochondrial protease ClpP in H3K27-altered, diffuse midline glioma.
Neuro Oncol
; 2023 Aug 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37589388
4.
ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma.
Cancer Res
; : OF1-OF17, 2023 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37195023
5.
ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma.
Cancer Res
; 2023 May 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37145169
6.
The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies.
Neuro Oncol
; 24(9): 1408-1422, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35481923
7.
B-cell Lymphoma 6 (BCL6): From Master Regulator of Humoral Immunity to Oncogenic Driver in Pediatric Cancers.
Mol Cancer Res
; 20(12): 1711-1723, 2022 12 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36166198